Seeking Clues to ResMed (RMD) Q1 Earnings? A Peek Into Wall Street Projections for Key Metrics

Core Insights - Analysts project ResMed (RMD) will report quarterly earnings of $2.49 per share, reflecting a 13.2% year-over-year increase, with revenues expected to reach $1.32 billion, an 8.1% increase from the same quarter last year [1]. Earnings Estimates - There has been a downward revision of 0.1% in the consensus EPS estimate over the last 30 days, indicating a collective reconsideration by analysts [2]. - Revisions to earnings projections are crucial for predicting investor behavior and are strongly linked to short-term stock price performance [3]. Revenue Projections - The consensus estimate for 'Global revenue- Total Sleep and Breathing Health' is $1.15 billion, representing an 8.1% increase year-over-year [5]. - 'Global revenue- Residential Care Software' is forecasted to reach $170.38 million, indicating an 8.7% increase from the prior year [5]. - 'Global revenue- Total Devices' is estimated at $666.36 million, reflecting a 6.5% year-over-year change [5]. Regional Revenue Insights - 'Global revenue- Total Masks and other' is projected at $484.35 million, showing a 9.6% increase from the previous year [6]. - 'U.S., Canada, and Latin America- Devices' is expected to reach $409.20 million, with a year-over-year change of 6.4% [6]. - 'U.S., Canada, and Latin America- Masks and other' is likely to be $355.76 million, indicating a 10.2% increase year-over-year [7]. - 'Combined Europe, Asia, and other markets- Total' is estimated at $385.76 million, reflecting a 7% year-over-year change [7]. - 'Combined Europe, Asia, and other markets- Devices' is projected at $257.17 million, indicating a 6.6% increase from the prior year [8]. - 'Combined Europe, Asia, and other markets- Masks and other' is expected to reach $128.59 million, suggesting a 7.9% year-over-year change [8]. - 'U.S., Canada, and Latin America- Total' is projected to be $764.96 million, reflecting an 8.2% increase year-over-year [9]. Stock Performance - Over the past month, shares of ResMed have returned -6.3%, contrasting with the Zacks S&P 500 composite's +3.8% change [9]. - ResMed currently holds a Zacks Rank 3 (Hold), indicating that its performance may align with the overall market in the near future [9].